Iris Nakamura
Biohacking Correspondent
Biohackers and the quantified-self crowd
Iris Nakamura covers the biohacking and quantified-self frontier — wearables, continuous monitoring, peptides and protocols — with a reporter's eye for which gadgets and claims the data actually supports.
Latest articles
Peptides Go Programmable: AI Diffusion Models Are Designing the Next Therapeutic Wave
A new class of generative models is treating peptide design like a search problem — and the early outputs hint at a faster, more targeted pipeline behind a quarter of all pharma.
Could a Pill Replace the Injection? The Race to Deliver Peptides Without Needles
GLP-1s rewrote metabolic medicine, but the syringe is still the weak link. New buccal devices and oral formulations are trying to close the gap — and the data is finally getting interesting.
GLP-1s Beyond Diabetes: New Meta-Analysis Maps Cardiovascular and Gynecologic Frontiers
A 2025 meta-analysis of 29 randomized trials suggests GLP-1 receptor agonists trim cardiovascular events in non-diabetic adults with obesity — while parallel reviews push the class into PCOS, perioperative care, and an experimental dual-receptor frontier.
Semaglutide's Expanding Map: Beyond Weight Loss to Heart, Skin, and Fat Biology
A wave of 2025 research suggests GLP-1 agonists are doing more than shrinking waistlines — nudging lipid panels, reshaping fat tissue, and edging into cardiology and dermatology. The signal is real, but still moderate.
Tirzepatide's Expanding Frontier: Lipids, Brain Pressure, and a New Safety Signal
The dual GIP/GLP-1 agonist is moving past weight loss into lipid repair and intracranial pressure relief. But a small case series flags a risk off-label users haven't been warned about.
The Surgeon's New GLP-1 Problem: What Patients on Semaglutide Should Know Before the OR
A fresh systematic review consolidates the perioperative signals — delayed gastric emptying, hypoglycemia, anesthesia risk — that every patient on a GLP-1 should bring up before surgery.
GLP-1's Second Act: Bone, Brain, and the Hypothalamic Frontier
Semaglutide and liraglutide are quietly migrating from diabetes clinics into stem-cell labs and rare-disease wards — even as a social-media-driven shortage exposes the cost of off-label demand.
The Next GLP-1 Wave: Oral Pills, Dual Agonists, and Nanofiber Depots
Weekly semaglutide rewrote metabolic medicine. The pipeline behind it — a small-molecule pill, a twin-receptor agonist, and an injectable depot that lasts weeks — is now coming into focus.